CN1152713C - 含有海藻糖的干燥的血液因子组合物 - Google Patents

含有海藻糖的干燥的血液因子组合物 Download PDF

Info

Publication number
CN1152713C
CN1152713C CNB961926600A CN96192660A CN1152713C CN 1152713 C CN1152713 C CN 1152713C CN B961926600 A CNB961926600 A CN B961926600A CN 96192660 A CN96192660 A CN 96192660A CN 1152713 C CN1152713 C CN 1152713C
Authority
CN
China
Prior art keywords
compositions
trehalose
factor
blood factor
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB961926600A
Other languages
English (en)
Other versions
CN1179107A (zh
Inventor
B��J����ɫ��
B·J·罗色尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Holdings Cambridge Ltd
Original Assignee
Quadrant Holdings Cambridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Holdings Cambridge Ltd filed Critical Quadrant Holdings Cambridge Ltd
Publication of CN1179107A publication Critical patent/CN1179107A/zh
Application granted granted Critical
Publication of CN1152713C publication Critical patent/CN1152713C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

一种稳定的血液因子组合物，它在不含有人血清白蛋白的条件下，含有稳定化量的海藻糖，以提供一种可稳定至60℃的制品。

Description

含有海藻糖的干燥的血液因子组合物
技术领域
本发明涉及血液因子的干燥的组合物，用于用水或水溶液重建(reconstitution)。
背景技术
血液因子，特别是因子VIII和因子IX，是目前治疗由缺少适当因子引起的疾病，特别是血友病的标准治疗药剂。血液因子一般是通过各种提取技术来源于人的血液的，例如EP-A-0083483中所公开的，或者通过在基因修饰的微生物中表达得到，例如EP-A-0160457和EP-A-0182448中所公开的。
血液因子制品(例如因子VIII)是非常敏感、不稳定的蛋白。它们通常是以溶于合适的缓冲液中的，冰冻的溶液的形式提供的，更一般地，它们是以冻干的粉末形式提供的。但甚至冻干的粉末在保存时也必须保持在低温下。为了使冻干的物质稳定，商业制品含有稳定化蛋白，特别是人血清白蛋白(HSA)。制备在环境温度和巴氏消毒(例如60℃)下稳定的，不含HSA的干燥的血液因子组合物被认为是不可能的。但是，HSA的存在将带来不可忽视的纯化方面的问题，因为蛋白不被病毒污染这一点是必需的。克服这些问题的重组HSA的应用是昂贵的。
发明内容
已知海藻糖是敏感蛋白的高效稳定剂，如US-A-4891319中所公开的，能够使蛋白在冰点以上的温度干燥。我们现已发现，在完全不含有HSA的条件下，如果用海藻糖来稳定血液因子制品，该制品不仅可以在冷冻或不冷冻的条件下干燥，并且甚至在60℃温度下持续一定时间后也是稳定的。因此，根据本发明，我们提供了稳定的干燥的血液因子组合物，该组合物含有稳定化量的海藻糖，不含有白蛋白。
通常可以应用任意稳定化量的海藻糖，过量一般不会带来问题。实际上，海藻糖的存在有助于再水化过程，它用于注射时是生理可接受的，能够迅速地被代谢成葡萄糖。该组合物对因子VIII的制剂是特别适用的，该制剂也可包含适当的缓冲盐或离子增强盐，特别是钙源。一般地，每单位的因子VIII对应大约1.0至1.5毫克钙离子的比率是合适的。
其他缓冲或改性剂(例如组氨酸)也可存在于干燥的物质中，用于重建成注射液。但是，我们发现盐(特别是氯化钠)的存在水平可影响干燥制品的保存性。用于注射的商业制品被认为需要具有等渗盐浓度。但是，冻建成注射液。但是，我们发现盐(特别是氯化钠)的存在水平可影响干燥制品的保存性。用于注射的商业制品被认为需要具有等渗盐浓度。但是，冻干的制剂最好是高渗的，典型地含有大约500mM NaCl(等渗NaCl＝150mM)，这被认为有助于稳定血液因子。结果，商业性冻干制剂通常具有高的盐含量，需用合适量的无菌水重建以得到等渗的溶液用于注射。
显著减少的盐含量对本发明的干燥的物质是优选的，需要干燥的每毫升大约500单位的因子III溶液通常优选地含有少于200mM，例如75-150mM的NaCl，特别是大约100mM，但是可低于例如20-50mM，特别是大约22-30mM。低盐制备物具有更高的干燥稳定性。可用盐溶液而不是常规的水将干燥制品重建到所需的盐浓度。海藻糖与盐的摩尔比通常应当高于1∶1，特别是高于2.5∶1，例如高于10∶1，优选地高于12.5∶1。
可通过干燥血液因子的适当溶液得到干燥的组合物，所述血液因子溶液含有正确比例的海藻糖和其他所需的成分。通常，被干燥的溶液应仅仅含有重建的注射溶液中所需的全部成分，虽然用于干燥的溶液不必处于同样的稀释度。典型地，每毫升用于干燥的溶液含有1-1000单位的因子III。干燥的方法可包括冻干、真空干燥和喷雾干燥。本发明特别优选的方法包括在不高于25℃，优选不高于10℃的温度下进行真空干燥，以形成泡沫，使暴露表面和干燥效果最大化。优选地，本发明的组合物每单位的血液因子含有0.15至2.5毫克的海藻糖。
下述实施例将进一步阐明本发明。
                      具体实施方式
实施例1
重组的因子VIII是以深度冷冻溶液的形式得到的，含有大约2000-2500单位/毫升，溶于制造者的高盐缓冲剂中。融化的溶液被透析，所用缓冲液含有500mM NaCl，15mM CaCl2和10mM组氨酸，pH6.8。在同样缓冲液中稀释透析后的蛋白，但是加入海藻糖，终浓度为每毫升500单位，10％重量比的海藻糖，pH6.8。该溶液以1毫升的等分试样被真空干燥。真空度从大气压逐级减少到4Pa(30mTorr)，以避免样品冷冻。在形成泡沫之前，样品的温度不允许超过12℃，在形成泡沫之后，温度保持在低于30℃。总的干燥时间是24小时至28小时。
样品在40℃下保存0、1.5、3和6个月，然后在进行活性检测之前用5毫升等分试样的无菌蒸馏水重建。结果显示于下表，与含有HSA的商品化冻干制品进行对比。受试样品和商品化样品都具有高的盐含量。干燥后的结果显示，在不含有HSA而含有海藻糖的条件下，虽然可以成功地干燥因子VIII，但即使在含有HSA时，高的盐含量对于长期保存也是不利的。
           初始活性的百分数
    时间(月)     样品     商业制品
    01.536     100.086.875.176.6     100.095.371.263.6
实施例2
如实施例1所述干燥样品，但所使用的缓冲制剂包含100mM NaCl，15mM CaCl2，15mM组氨酸和1.27摩尔海藻糖(43.5w/v)，并在重建之前保存在60℃。结果显示在下表中，其中活性是在ACL 100自动凝度计(Instrumentation Laboratory SpA，Milan，Italy)上测量的。即使在60℃下保存4周之后，具有低盐含量的受试样品也没有显示出明显的活性损失。
   恢复的初始活性的百分数
    湿性对照     1000
    干燥后2周4周     95.596.096.8
实施例3
制备含有如下不同盐浓度的两种制剂：
            制剂A                         制剂B
NaCl                0.13％         NaCl            1.03％
CaCl2              0.011％        CaCl2          0.011％
L-组氨酸            0.12％         L-组氨酸        0.12％
Tris                0.002％        Tris            0.002％
Tween 80            0.002％        Tween 80        0.002％
PEG 3350            0.004％        PEG 3350        0.004％
海藻糖              7.5％          海藻糖          7.5％
因子VIII            50U/ml         因子VIII        50U/ml
加水至100％                        加水至100％
将10毫升的制剂分配到各个30毫升的瓶中，使得因子VIII的浓度为500单位/瓶。
冻干是在Laconco(Lyph-lock 12 stoppering)冻干机中进行的。开始时，样品被冷却至-40℃，然后在加温至-35℃之前被置于真空。80小时之后，以2.5℃/小时的速率将样品加温，直到搁板温度达到25℃。然后在封闭之前，在真空下将样品保持在25℃两小时，并从干燥机中移出。
干燥之后，用10毫升水将样品重新水化，测定两次(测定l和2)因子VIII的浓度。结果由下表给出，以因子VIII浓度相对于预补充(prefill)对照(在-70℃下冷冻)的百分数表示。从该结果可以看出，因子VIII可以在不含有HSA的，基于海藻糖的制剂中被成功地冻干。
    样品     测定1     测定2
    制剂A制剂B     77％9l％     85％94％

Claims (13)

1.一种稳定的、冻干的血液因子组合物，其含有稳定化量的海藻糖，不含有白蛋白，所述血液因子是因子VIII。
2.权利要求1的组合物，其中每单位的血液因子含有0.15至2.5毫克的海藻糖。
3.权利要求1或2的组合物，其含有NaCl，其中海藻糖与NaCl的摩尔比高于1∶1。
4.权利要求3的组合物，其中每摩尔氯化钠含有超过2.5摩尔的海藻糖。
5.权利要求3的组合物，其中每摩尔氯化钠含有超过10摩尔的海藻糖。
6.权利要求1的组合物，其中每单位的因子VIII含有1.0至1.5微克的钙离子。
7.制备权利要求1的组合物的方法，其中含有海藻糖的血液因子的水溶液是在不超过25℃的温度下被干燥的。
8.权利要求7的方法，其中温度不超过10℃。
9.制备权利要求1的组合物的方法，其包括使因子VIII的水溶液干燥，所述溶液含有海藻糖和每单位因子VIII低于0.4mM的NaCl。
10.制备用于注射的含有血液因子的治疗组合物的方法，其包括重建权利要求1的组合物。
11.权利要求10的方法，其中组合物是用水重建的。
12.权利要求10的方法，其中组合物是用盐水重建的。
13.权利要求1的组合物在制备注射用含血液因子的治疗组合物中的用途，所述组合物用于治疗血友病。
CNB961926600A 1995-01-19 1996-01-19 含有海藻糖的干燥的血液因子组合物 Expired - Lifetime CN1152713C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition
GB9501040.1 1995-01-19

Publications (2)

Publication Number Publication Date
CN1179107A CN1179107A (zh) 1998-04-15
CN1152713C true CN1152713C (zh) 2004-06-09

Family

ID=10768253

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB961926600A Expired - Lifetime CN1152713C (zh) 1995-01-19 1996-01-19 含有海藻糖的干燥的血液因子组合物

Country Status (15)

Country Link
US (2) US6649386B2 (zh)
EP (4) EP1308170B1 (zh)
JP (1) JP3898221B2 (zh)
KR (1) KR100417593B1 (zh)
CN (1) CN1152713C (zh)
AT (2) ATE413885T1 (zh)
AU (1) AU704317B2 (zh)
CA (2) CA2671383C (zh)
DE (2) DE69637749D1 (zh)
DK (2) DK1308170T3 (zh)
ES (2) ES2316658T3 (zh)
GB (1) GB9501040D0 (zh)
PT (2) PT871476E (zh)
SI (1) SI1308170T1 (zh)
WO (1) WO1996022107A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US7799765B2 (en) * 2001-08-10 2010-09-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Association compound of trehalose or maltitol with metal ion compound
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2557061C (en) * 2004-03-19 2013-08-20 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
CA2567720A1 (en) 2004-05-24 2005-12-08 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
EP2114379A2 (en) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2991162A1 (en) * 2007-12-21 2009-07-02 Aptevo Biotherapeutics Llc Stabilized factor ix formulations containing trehalose
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
JP2012501681A (ja) 2008-09-12 2012-01-26 ジェンボールト コーポレイション 生体分子の貯蔵および安定化のためのマトリックスおよび媒体
PT2349314E (pt) 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
CN103782151A (zh) * 2011-07-13 2014-05-07 德纳托股份公司 流体生物样品的稳定化方法
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3082769B1 (en) * 2013-12-19 2018-01-31 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
AU2015299224B2 (en) 2014-08-04 2019-06-20 Csl Limited Factor VIII formulation
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
US4891319A (en) 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
AU650045B2 (en) * 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP1652534A3 (en) * 1992-10-02 2007-05-02 Genetics Institute, LLC Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina

Also Published As

Publication number Publication date
PT1308170E (pt) 2008-12-26
DE69637749D1 (de) 2008-12-24
GB9501040D0 (en) 1995-03-08
SI1308170T1 (sl) 2009-04-30
ATE413885T1 (de) 2008-11-15
JP3898221B2 (ja) 2007-03-28
ES2316658T3 (es) 2009-04-16
EP0871476A1 (en) 1998-10-21
KR19980701500A (ko) 1998-05-15
EP1308170A3 (en) 2004-03-03
KR100417593B1 (ko) 2004-04-30
US20090149388A1 (en) 2009-06-11
CA2671383A1 (en) 1996-07-25
PT871476E (pt) 2003-12-31
CA2210872C (en) 2009-09-08
EP2258402A2 (en) 2010-12-08
EP1308170A2 (en) 2003-05-07
DK0871476T3 (da) 2003-11-10
EP1308170B1 (en) 2008-11-12
ES2202425T3 (es) 2004-04-01
EP2258402A3 (en) 2011-01-05
US6649386B2 (en) 2003-11-18
EP0871476B1 (en) 2003-07-23
US7803911B2 (en) 2010-09-28
EP1974741A1 (en) 2008-10-01
AU4454096A (en) 1996-08-07
CA2210872A1 (en) 1996-07-25
WO1996022107A1 (en) 1996-07-25
AU704317B2 (en) 1999-04-22
ATE245442T1 (de) 2003-08-15
CA2671383C (en) 2012-04-24
DE69629209T2 (de) 2004-02-19
US20020128207A1 (en) 2002-09-12
DK1308170T3 (da) 2008-12-15
DE69629209D1 (de) 2003-08-28
CN1179107A (zh) 1998-04-15
JPH11503719A (ja) 1999-03-30

Similar Documents

Publication Publication Date Title
CN1152713C (zh) 含有海藻糖的干燥的血液因子组合物
US7381796B2 (en) Dried blood factor composition comprising trehalose
US7879805B2 (en) High temperature stable peptide formulation
CN1130224C (zh) 低糖份、稳定的、不含白蛋白的一种重组体凝血因子制剂
CN100448482C (zh) Hgf冻干制剂
CZ293527B6 (cs) Formulace s obsahem koagulačního faktoru VIII a způsob její přípravy
JP3953102B2 (ja) 凝固因子ｖｉｉｉもしくは因子ｉｘを水溶液中に含む蛋白質処方物
CA2683317C (en) Stabilization of liquid solutions of recombinant protein for frozen storage
CN101578106A (zh) Hgf制剂
US7244824B2 (en) Dried blood factor composition comprising trehalose
JPH0543689B2 (zh)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040609

EXPY Termination of patent right or utility model